These are the kind of decisions we need to make for the best interest's of Cellceutix and its shareholders. That is why we have filed a S-3 for a shelf offering. If shorts think they can can cover with cheaper shares because of this filing, they may be in for a surprise as we will always do whats best for Cellceutix and its shareholders. - CTIX CEO
More confirmation that the S-3 will be used wisely, and with consideration for what's best for shareholders.
Copy that. And 95% of posters here are saying they're investors so this euphoria and angst over minute by minute or daily pops and drops is strange to me.
Karin, thank you for sharing and I agree with TOB and others in following management's lead on shareholder value.
What I find intriguing is Leo's comment that Durata's buyout share price was astonishing at $23. I can't decide if he thinks this is a very good price or he feels that it was too much considering the science that they offer as to how it compares to the value of the B platform.
I guess we'll see how this unfolds and once again, thanks!